Kayentis Offers Carbon-Neutral eCOA Suggestions
Kayentis, a global provider of eCOA solutions for clinical trials headquartered in France, has announced the launch of a set of initiatives to evaluate the carbon footprint of each clinical trial services eCOA component it conducts and propose solutions to clients on limiting the CO2 emissions of these eCOA projects.
Guillaume Juge, CEO of Kayentis. “While the solutions to reduce the impact of carbon emissions require closer collaboration with our customers, they have no impact on the cost of the study, nor will they lessen the quality or timeliness of the service we provide.” Some eCOA options, depending on the protocol include:
- A webCOA back-up strategy, using an online platform to directly enter patient data rather than stockpile spare devices on each site, or even centralize them at the country level
- Replacing onsite training and face-to-face meetings with virtual ones
- Using refurbished devices - as the lifespan of a device is around four years, refurbishing is a feasible solution for both short-term studies and to replace a device during the course of a study
For more information click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
